Cost-cutting generics and biosimilars stuck in legal limbo
Many believe that the biosimilar industry can address the issue of spiraling drug costs, but first it has to make it through a thicket of challenges.
Gilead Sciences to launch authorized generics of two hepatitis C drugs
The authorized generics, announced amid HCV product pricing pressures, will cost $24,000 - less than one-third the branded drugs' prices - to reflect discounts given to payers.
presented by
Closing the Quality-Affordability Gap in Workplace Mental Health
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.